Kodiak Sciences Inc. (KOD)
Market: NASD |
Currency: USD
Address: 1200 Page Mill Road
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Show more
📈 Kodiak Sciences Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.25
-
Upside/Downside from Analyst Target:
105.38%
-
Broker Call:
-4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
10-25%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Kodiak Sciences Inc.
| Date | Reported EPS |
|---|
| 2026-05-12 (estimated upcoming) | - |
| 2026-03-25 (estimated upcoming) | - |
| 2025-11-12 (estimated upcoming) | - |
| 2025-11-11 (estimated upcoming) | - |
| 2025-08-12 (estimated upcoming) | - |
| 2025-08-12 (estimated upcoming) | - |
| 2025-08-11 (estimated upcoming) | - |
| 2025-05-14 | -1.09 |
| 2025-05-13 | - |
| 2025-05-12 | - |
| 2025-03-27 | -0.84 |
| 2025-03-25 | - |
| 2024-11-14 | -0.84 |
| 2024-08-14 | -0.86 |
| 2024-08-13 | -0.86 |
| 2024-05-15 | -0.82 |
| 2024-05-14 | -0.82 |
| 2024-03-28 | -1.13 |
| 2024-03-27 | -1.13 |
| 2023-11-14 | -0.95 |
| 2023-11-13 | -0.95 |
| 2023-08-14 | -1.53 |
| 2023-08-13 | -1.53 |
| 2023-05-15 | -1.35 |
| 2023-05-14 | -1.35 |
| 2023-03-28 | -1.35 |
| 2023-03-27 | -1.35 |
| 2022-11-09 | -1.47 |
| 2022-11-08 | -1.47 |
| 2022-08-09 | -1.74 |
| 2022-08-08 | -1.74 |
| 2022-05-10 | -1.83 |
| 2022-05-09 | -1.83 |
| 2022-03-01 | -1.79 |
| 2022-02-28 | -1.79 |
| 2021-11-09 | -1.3 |
| 2021-11-08 | -1.3 |
| 2021-08-09 | -1.08 |
| 2021-08-08 | -1.08 |
| 2021-05-10 | -0.98 |
| 2021-05-09 | -0.98 |
| 2021-03-01 | -0.97 |
| 2021-02-28 | -0.97 |
| 2020-11-09 | -0.8 |
| 2020-11-08 | -0.8 |
| 2020-08-10 | -0.58 |
| 2020-08-09 | -0.58 |
| 2020-05-11 | -0.54 |
| 2020-05-10 | -0.54 |
| 2020-03-15 | -0.4 |
| 2019-11-11 | -0.33 |
| 2019-08-13 | -0.31 |
| 2019-05-14 | -0.21 |
| 2019-03-26 | -0.25 |
| 2018-11-15 | - |
| 2018-10-04 | - |
📰 Related News & Research
No related articles found for "kodiak sciences".
